Extraordinarily high serum CA 19-9 in setting of pancreatic necrosis and underlying pancreatic adenocarcinoma: a case report

被引:0
|
作者
McConnell, Ashlyn [1 ]
Stoneman, Tyler [2 ]
Hewlett, Stanley [1 ]
机构
[1] Princeton Baptist Med Ctr, Dept Surg, Birmingham, AL 35211 USA
[2] Edward Via Coll Osteopath Med, Spartanburg, SC 29303 USA
来源
JOURNAL OF SURGICAL CASE REPORTS | 2023年 / 2023卷 / 10期
关键词
pancreatic cancer; CA; 19-9; jaundice; tumor markers;
D O I
10.1093/jscr/rjad550
中图分类号
R61 [外科手术学];
学科分类号
摘要
Carbohydrate antigen (CA 19-9) is the most validated marker for both sensitivity and specificity of pancreatic adenocarcinoma used to aid diagnosis of symptomatic patients as well as to evaluate the progression or treatment of disease. Though higher levels of CA 19-9 tend to correlate with neoplastic disease, elevated levels are also often seen in patients with benign gastrointestinal diseases, such as obstructive jaundice and pancreatitis. We present a case of a 74-year-old male who was admitted for abdominal pain and worsening jaundice who was diagnosed with extensive pancreatic necrosis and an underlying invasive pancreatic adenocarcinoma whose serum level of CA 19-9 was found to be extraordinarily high.
引用
收藏
页数:2
相关论文
共 50 条
  • [1] Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
    Lee, Kyong Joo
    Yi, Seung Woo
    Chung, Moon Jae
    Park, Seung Woo
    Song, Si Young
    Chung, Jae Bock
    Park, Jeong Youp
    YONSEI MEDICAL JOURNAL, 2013, 54 (03) : 643 - 649
  • [2] Serum CA 19-9 as Predictor in Preoperative Parameters for Resectable Pancreatic Adenocarcinoma
    Itakura, J.
    Watanabe, M.
    Hosomura, N.
    Amemiya, H.
    Kawaida, H.
    Okamoto, H.
    Kohno, H.
    Ichikawa, D.
    PANCREAS, 2018, 47 (10) : 1395 - 1395
  • [3] Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
    Brian A. Boone
    Jennifer Steve
    Mazen S. Zenati
    Melissa E. Hogg
    Aatur D. Singhi
    David L. Bartlett
    Amer H. Zureikat
    Nathan Bahary
    Herbert J. Zeh
    Annals of Surgical Oncology, 2014, 21 : 4351 - 4358
  • [4] CA 19-9 as a predictor of TNM stage for pancreatic adenocarcinoma
    Kowalski, T
    Loren, D
    Raza, A
    Setty, S
    Rosato, E
    GASTROENTEROLOGY, 2004, 126 (04) : A30 - A30
  • [5] Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
    Boone, Brian A.
    Steve, Jennifer
    Zenati, Mazen S.
    Hogg, Melissa E.
    Singhi, Aatur D.
    Bartlett, David L.
    Zureikat, Amer H.
    Bahary, Nathan
    Zeh, Herbert J., III
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (13) : 4351 - 4358
  • [6] CA 19-9 serum course and prognosis of pancreatic cancer
    Safi, F
    Schlosser, W
    Falkenreck, S
    Beger, HG
    INTERNATIONAL JOURNAL OF PANCREATOLOGY, 1996, 20 (03) : 155 - 161
  • [7] Should High Serum CA 19-9 Levels Preclude Surgery in Patients with Resectable Pancreatic Head Adenocarcinoma?
    Turrini, Olivier
    Schmidt, C. Max
    Moreno, Jose A.
    Parikh, Purvi
    House, Michael
    Zyromski, Nicholas J.
    Nakeeb, Attila
    Howard, Thomas J.
    Pitt, Henry A.
    Lillemoe, Keith D.
    GASTROENTEROLOGY, 2009, 136 (05) : A895 - A895
  • [8] Serum CA 19-9 Is a Powerful Discriminator of Pancreatic Adenocarcinoma in Patients Referred for ERCP or EUS With Suspected Pancreatic Cancer
    Kwon, Richard S.
    Choksi, Neel
    Scheiman, James M.
    Piraka, Cyrus R.
    Elta, Grace H.
    Elmunzer, B. Joseph
    Young, Benjamin E.
    Prabhu, Anoop
    Wamsteker, Erik-Jan
    Harthun, Kenneth G.
    Brenner, Dean E.
    Anderson, Michelle A.
    GASTROENTEROLOGY, 2013, 144 (05) : S658 - S658
  • [9] Determination of CA 19-9 Antigen in Serum and Pancreatic Juice for Differential Diagnosis of Pancreatic Adenocarcinoma From Chronic Pancreatitis
    Malesci, Albert
    Tommasini, Maurizio A.
    Bonato, Claudio
    Bocchia, Paola
    Bersani, Maurizo
    Zerbi, Alessandro
    Beretta, Edoardo
    Di Carlo, Valerio
    GASTROENTEROLOGY, 1987, 92 (01) : 60 - 67
  • [10] CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma
    Ali C.W.
    Kaye T.F.
    Adamson D.J.A.
    Tait I.S.
    Polignano F.M.
    Highley M.S.
    Journal of Gastrointestinal Cancer, 2007, 38 (2-4) : 108 - 114